Impact of the COVID-19 Pandemic on Drug Use and Monitoring of Cancer Patients

NCT05069662 | Completed

• 1 other identifier: 69HCL21_0163
• Study Type: observational
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

The COVID-19 pandemic has profoundly changed the organisation of care. Teleconsultation has replaced hospital medical consultations in order to reduce the risk of patient exposure to the virus. Within the framework of the Oncoral multidisciplinary outpatient / hospital program of follow-up, carried out by the Hospices Civils de Lyon for ambulatory patients treated with oral anticancer drugs, interviews with the pharmacist and/or nurse, which were previously organised face-to-face, have been replaced by telephone interviews, ensuring continuity of follow-up for patients without having to come to the hospital. This study focuses on a telephone survey to describe the impact of the COVID-19 pandemic health crisis on the drug exposure of cancer patients followed in the Oncoral program, their treatment management, their perception of teleconsultation and their IT resources for remote monitoring.

Conditions

Cancer

Keywords

remote monitoring; oral anticancer drugs; drug intake; COVID-19 pandemic

Outcome Measures

Primary Outcomes (1)

• Percentage of patients reporting a change in drug use during the COVID-19 pandemic-related containment period.

  Percentage of patients reporting a change in medication use and / or a change medication management and / or a change in oral anticancer drug adherence during the COVID-19 pandemic-related containment period.

  Inclusion

Study Arms (1)

Patients treated with oral anticancer drugs

Patients treated with oral anticancer drugs followed in the Oncoral program

Other: Directive Interview

Interventions

Directive Interview OTHER

One directive interview conducted by telephone

Patients treated with oral anticancer drugs

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients treated with oral cancer drugs included in the Oncoral multidisciplinary outpatient / hospital program of the Hospices Civils de Lyon and having benefited from remote monitoring during the COVID-19 pandemic-related containment period between March 16, 2020 and May 11, 2020.

You may qualify if:

• Adult patients aged 18 and over
• Ambulatory patients treated with oral anticancer drugs and benefiting from the ONCORAL multidisciplinary outpatient / hospital program
• Having benefited from a remote monitoring between March 16, 2020 and May 11, 2020 (the COVID-19 pandemic-related containment period)
• Patients who do not object to participating in the survey and to the use of the data collected

You may not qualify if:

• Patients who do not speak French
• Patients living in an institution
• Patients protected by law
• Patients included in a drug clinical trial
• Patients refusing to participate in the survey and / or not responding to the 2 telephone calls requesting their participation and / or not responding to any of these calls
• Patients choosing to stop the interview and no longer answering to the questions asked

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (1)

Service Pharmaceutique, Hospices Civils de Lyon

Pierre-Bénite, 69495, France

Location

MeSH Terms

Conditions

Neoplasms; COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 4, 2021
• First Posted: October 6, 2021
• Study Start: October 5, 2021
• Primary Completion: January 5, 2022
• Study Completion: January 5, 2022
• Last Updated: January 11, 2022

Record last verified: 2022-01

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)